Saturday 17 October 2026
Export RXST’s income statement to Excel — free account
RxSight, Inc.
RXST Healthcare Medical Devices
RxSight, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $134.5 million, down 3.89% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS was flat and free cash flow fell 94.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
4.51
0.16
−3.43%
Follow RXST
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.57 | 2.00 | 3.17 | 2.59 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(20.97) | (23.36) | (381.42) | (310.26) | |
P/B ratio |
0.76 | 0.95 | 1.54 | 1.33 | |
Price to Tangible BV |
0.76 | 0.95 | 1.54 | 1.33 | |
EV/Sales |
0.08 | 0.44 | 1.61 | 1.13 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.47) | (3.20) | (14.00) | (8.60) | |
EV/FCF |
(0.40) | (2.60) | (11.23) | (7.22) | |
Quick Ratio |
3.57 | 8.78 | 9.58 | 11.29 | |
Current Ratio |
4.07 | 10.20 | 10.95 | 12.74 | |
Net Debt/EBITDA |
14.38 | 11.56 | 18.52 | 16.89 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.39 | 0.41 | 0.43 | 0.46 | |
Operating CF/Net income |
0.79 | 0.69 | 0.12 | 0.12 | |
Capex/Depreciation |
2.60 | 0.74 | 1.16 | 0.45 | |
Interest Coverage |
(4,590.00) | (5,943.00) | (2,834.00) | (3,044.50) | |
Research and Development Expense of Revenue |
27.38% | 30.66% | 27.31% | 29.86% | |
Selling, General and Administrative Expense of Revenue |
90.15% | 103.11% | 84.93% | 90.13% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
22.12% | 25.72% | 23.97% | 26.72% | |
Graham Net Nets |
1.19 | 0.95 | 0.59 | 0.68 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(23.44%) | (18.34%) | (9.12%) | (9.79%) | |
Free Cash Flow Yield |
(13.58%) | (8.48%) | (4.54%) | (6.03%) | |
Revenue per Share |
0.81 | 0.75 | 0.80 | 0.74 | |
Operating CF per Share |
(0.23) | (0.26) | (0.03) | (0.03) | |
Capex per Share |
(0.05) | (0.02) | (0.03) | (0.01) | |
Free Cash Flow per Share |
(0.28) | (0.28) | (0.06) | (0.04) | |
Cash per Share |
5.03 | 5.27 | 5.58 | 5.55 | |
Shareholders Equity per Share |
6.35 | 6.47 | 6.75 | 6.74 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.35 | 6.47 | 6.75 | 6.74 | |
Free Cash Flow |
(11.49) | (11.65) | (2.25) | (1.77) | |
Working Capital |
246.95 | 251.85 | 261.21 | 261.59 | |
Capital Expenditures |
(1.96) | (0.76) | (1.14) | (0.58) | |
Net Current Asset Value |
238.04 | 242.53 | 251.33 | 251.31 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.06 | 0.02 | 0.03 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
53.29 | 26.70 | 26.72 | 24.76 | |
Average Payables |
4.85 | 7.12 | 4.92 | 3.98 | |
Average Inventory |
31.09 | 29.22 | 26.78 | 25.31 | |
Average Assets |
330.85 | 308.52 | 315.19 | 309.50 | |
Average Common Equity |
270.68 | 273.31 | 278.46 | 276.62 |
Columns are period end dates